Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer

International Journal of Radiation Oncology, Biology, Physics
Nirdosh Kumar GognaTanya Holt

Abstract

Local progression, in patients with hormone-refractory prostate cancer, often causes significant morbidity. Pelvic radiotherapy (RT) provides effective palliation in this setting, with most published studies supporting the use of high-dose regimens. The aim of the present study was to examine the role of split-course hypofractionated RT used at our institution in treating this group of patients. A total of 34 men with locoregionally progressive hormone-refractory prostate cancer, treated with a split course of pelvic RT (45-60 Gy in 18-24 fractions) between 2000 and 2008 were analyzed. The primary endpoints were the response rate and actuarial locoregional progression-free survival. Secondary endpoints included overall survival, compliance, and acute and late toxicity. The median age was 71 years (range, 53-88). Treatment resulted in an overall initial response rate of 91%, a median locoregional progression-free survival of 43 months, and median overall survival of 28 months. Compliance was excellent and no significant late toxicity was reported. The split course pelvic RT described has an acceptable toxicity profile, is effective, and compares well with other high-dose palliative regimens that have been previously reported.

References

Nov 1, 1990·British Journal of Urology·H G KynastonP N Matthews
Nov 1, 1995·International Journal of Radiation Oncology, Biology, Physics·S P LankfordG K Zagars
Nov 1, 1995·British Journal of Urology·B OtnesS D Fosså
May 5, 1999·International Journal of Urology : Official Journal of the Japanese Urological Association·Y FuruyaH Ito
May 19, 2001·Best Practice & Research. Clinical Obstetrics & Gynaecology·S C Smith, W J Koh
Dec 18, 2007·Seminars in Radiation Oncology·Edward F Miles, W Robert Lee
May 26, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Omar S DinPeter Kirkbride

❮ Previous
Next ❯

Citations

Apr 30, 2013·Surgical Oncology Clinics of North America·Bridget F Koontz, W Robert Lee
Dec 3, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·R WhiteF Foroudi
Jun 30, 2016·International Journal of Surgery·Alfonso ReginelliSalvatore Cappabianca
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen T LutzEdward Chow
Jul 15, 2015·Therapeutic Advances in Urology·Jim N Rose, Juanita M Crook
Mar 21, 2018·International Journal of Clinical Oncology·Rihito AizawaTakashi Mizowaki
May 7, 2021·Scientific Reports·Mami OgitaKeiichi Nakagawa
Nov 29, 2020·Clinical Genitourinary Cancer·Raj R BhanvadiaAditya Bagrodia
Jun 1, 2021·Surgical Oncology Clinics of North America·Graeme R WilliamsJoshua A Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Omar S DinPeter Kirkbride
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Marte Grønlie CameronIngvild Vistad
© 2022 Meta ULC. All rights reserved